Sat, Aug 2, 2014, 12:12 AM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

NanoViricides, Inc. Message Board

  • doc.feelgoode doc.feelgoode May 11, 2012 12:56 PM Flag

    From Dr. Diwan, President NNVC...

    From Dr. Diwan, President NNVC and inventor of the underlying newly patented technology and other NNVC licensed patent applications:

    Email, Thursday, May 10, 2012

    The critical and important difference from these and many other technologies out there and nanoviricides® is that nanoviricides are not just polymer-based technologies.

    Getting a polymer to bind to a specific site on a virus or a cell is not difficult. It can be accomplished with many polymers. However, most such polymers allow a ligand to be attached only at one or both ends of the polymer chain, resulting in a relatively low ligand density. In contrast, the patent describes novel polymers in which we can attach ligands at every repeat unit. This is a major innovation and has not been accomplished before. Binding to a polymer bearing ligands vs the cell surface receptors is the competition that the antiviral agent must win. The balance is strongly in favor of nanoviricides(r) due to the high ligand density we can theoretically accomplish.

    It is not enough to bind to the virus. Such binding would create what may be termed a "precipitate" that would lead to an immune precipitate if the complement system is properly functioning, and then could get cleared by the immune system if the immune system is properly functioning at full capacity. We know from Virology that viruses are intelligent nanomachines and that they succeed in creating a severe infection in a human host only if they succeed in fighting out the host immune system. Most viruses derail the immune system in some way, and there are many different points where they derail it.

    Most approaches being tried currently are based on rigid polymers. Examples- dendrimers, polylactate/polybutyrate and related polymers. The drugs based on these are essentially rigid particles. So the liganded polymer nanoparticle of such could stops at binding to the virus. It may bind to the more than one virus particles, itself appearing like a marble in the middle. However, their surface of interaction with an individual virus particle is small; it is only a tangential interaction.

    The second and even more important key invention in our polymers is that they do not form fixed, rigid particles. They are "metastable" materials. What this means is that put a nanoviricide in water or aqueous phase (as in bodily fluids) and it would appear with ligands displayed outwards and the lipid chains hidden inside. If you put it in a lipidic environment (fatty/oily environment or organic solvent), it inverts itself inside out, and throws its lipid feet outside and pulls its water-loving parts inside. This is the key feature that allows for a strong interaction with a lipid surface such as virus. Upon binding to the virus, we believe that this metastability property enables the polymeric micelle to spread itself along the virus surface, becoming so thin that the lipid part of the polymer contacts the lipid coat on the virus. Then a well-known switching process called "lipid-lipd fusion" can take place. Many viruses are susceptible to such attack and would fall apart completely [typically, these are viruses that do not require excessive acidification before dismantling themselves in the natural course of infection].

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Just trying to be helpful...

    • well you are quite the charmer I see

      good luck to ya

    • Well, either way meh is a loser...

      Vested in NNVC @.67 = Loser.
      Posting as fake investor = Loser.
      Feeling honored anyone takes interest in his/her posts = Loser.
      Defending NNVC (a total POS company with zero value) = Loser.

    • I am honored to be such a suspicious character, thank you. I feel like a real man of mystery now.

    • The poster meh76_1999 is suspicious. I am not sure why he has given details about his fabricated trading approach to NNVC. It seems to be suggestive, likely a pumper's comment.

    • "due to the high ligand density we can theoretically accomplish."

      This makes NNVC stock theoretically worth how much?

    • Worthless patent, no matter what he's saying. No real novelty as there are patents in polymers. They need to have a drug. If NNVC had to sell the patent I cant see anyone paying over $100,000. Someone may offer more based on the data they have. Pretox, NNVC has limited value.
      Huntsville, AL Serina Therapeutics, Inc. President and CEO Randall Moreadith, MD, PhD,
      reported today that Serina has closed on a $ 9.5 million financing round to advance its lead
      oncology candidate SER-203 into a Phase I study in humans in early 2012.
      “We are pleased to report to our existing and new shareholders the closing of the Series A-2
      financing round that was launched in late 2010. This is a very significant milestone for Serina
      Therapeutics, and will allow us to advance our lead oncology candidate into Phase I and continue
      to build a robust pipeline of novel polymer therapeutics for unmet medical needs,” stated Dr.
      “Serina’s patented polymer technology has enormous potential to advance novel polymer drugs,
      not just for oncology but for many diseases including metabolic disorders, pain and
      inflammation. This capital gives us sufficient resources to advance our first molecule into the
      clinic, and we wish to express our sincere appreciation to our shareholders.”
      Serina Therapeutics, Inc. is an incubator company located at the Hudson-Alpha Institute for
      Biotechnology in Huntsville, Alabama, and is the only company in the world to develop
      polyoxazoline (POZ) polymers for pharmaceutical applications. POZ polymers are
      multifunctional polymers that can be coupled to known drugs, and in doing so these novel
      therapeutics have dramatically altered pharmacokinetics. Molecules that normally have short
      duration times in the body can be converted to molecules with prolonged activity – sometimes as
      long as weeks. This prolonged half-life in the body may improve the safety and efficacy of the
      molecule. In addition, Serina has developed technology that allows the resulting polymer drug to
      be specifically targeted to receptors on the surface of cells, and this approach may be useful for
      applications outside oncology. F

      • 2 Replies to drbrainydude
      • I guess you didn't read the patent or Dr. Diwan's explanation. I guess you dont know the 31 claims and how broad they can be interpreted. The polymer micelle is the drug. He talked about other polymers and explained how his is very different. But I guess you missed it. The micelle is flexible and soft enough to spread across a virus surface. It will last and be effective for weeks. When the technology is finally accepted this will be ground breaking. Your company is in oncology not virology. Nearly all other polymer developers are in oncology and drug delivery. A nanoviricide is the drug.

4.16+0.10(+2.46%)Aug 1 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.